Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 04:36:45时区推断·⟳ 抓取 04:38:51·⚡ 决策 07-23 04:41:46 +2m55s·96.6 天前
FDA受理辉瑞TALZENNA联合XTANDI前列腺癌扩适应症申请并授予优先审评
FDA只是受理补充新药申请并设定2026年四季度PDUFA日期，尚非批准上市。
📄 原文Investing.com↗ 原文
FDA accepts Pfizer filing for Talzenna-Xtandi prostate cancer use
Stocks end slightly lower as wary traders make small moves with eyes on earnings NEW YORK - Pfizer Inc. (NYSE:PFE) anno…
不做 辉瑞（PFE.US）
FDA受理不是批准，且辉瑞市值过大、未披露扩适应症销售增量，短线无足够edge。
不做 安斯泰来制药（4503.JP）
XTANDI合作方受益方向成立，但审批仍待2026年四季度且新增业绩量级未披露，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-22 · 扩散 medium · price-in 风险 medium ↗
关键理由
- FDA只是受理补充新药申请并设定2026年四季度PDUFA日期，尚非批准上市。
- TALAPRO-3显示影像学进展或死亡风险下降52%，但该疗法已在更晚期mCRPC获批，本次是向更早期mCSPC扩展。
- 辉瑞和安斯泰来均为大市值药企，正文未披露新增患者数、定价、分成或销售峰值，难证明短期市值级增量。
主要风险
- 最终FDA审批仍在2026年四季度，交易窗口太长。
- ASCO和NEJM数据已披露，受理本身的新信息量有限。
原文全文
展开原文 · 2,032 字
Stocks end slightly lower as wary traders make small moves with eyes on earnings
NEW YORK - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration accepted for Priority Review a supplemental New Drug Application for TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer.
The FDA set a Prescription Drug User Fee Act action date in the fourth quarter of 2026, according to a press release statement.
The combination is currently approved in the U.S. for men with HRR gene-mutated metastatic castration-resistant prostate cancer. The supplemental application seeks to expand use to metastatic castration-sensitive prostate cancer, an earlier stage of disease.
The application is supported by data from the Phase 3 TALAPRO-3 trial, which enrolled 599 patients at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The trial showed TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI. The safety profile was consistent with the known profiles of each agent with no new safety signals identified.
Results from the trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine.
The use of TALZENNA plus XTANDI in HRR gene-mutated metastatic castration-sensitive prostate cancer is also under review by the European Medicines Agency. TALZENNA plus XTANDI is currently approved for metastatic castration-resistant prostate cancer in more than 60 countries, with specific indications varying by country.
TALZENNA is an oral poly ADP-ribose polymerase inhibitor, while XTANDI is an androgen receptor pathway inhibitor. The combination therapy is part of a collaboration between Pfizer and Astellas that began in October 2009.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
NEW YORK - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration accepted for Priority Review a supplemental New Drug Application for TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer.
The FDA set a Prescription Drug User Fee Act action date in the fourth quarter of 2026, according to a press release statement.
The combination is currently approved in the U.S. for men with HRR gene-mutated metastatic castration-resistant prostate cancer. The supplemental application seeks to expand use to metastatic castration-sensitive prostate cancer, an earlier stage of disease.
The application is supported by data from the Phase 3 TALAPRO-3 trial, which enrolled 599 patients at sites in the U.S., Canada, Europe, South America, and the Asia-Pacific region. The trial showed TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% versus placebo plus XTANDI. The safety profile was consistent with the known profiles of each agent with no new safety signals identified.
Results from the trial were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine.
The use of TALZENNA plus XTANDI in HRR gene-mutated metastatic castration-sensitive prostate cancer is also under review by the European Medicines Agency. TALZENNA plus XTANDI is currently approved for metastatic castration-resistant prostate cancer in more than 60 countries, with specific indications varying by country.
TALZENNA is an oral poly ADP-ribose polymerase inhibitor, while XTANDI is an androgen receptor pathway inhibitor. The combination therapy is part of a collaboration between Pfizer and Astellas that began in October 2009.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。